Histoindex

HistoIndex is a Singapore-based medical technology company established in 2010 as a spin-off from the Agency for Science, Technology and Research (A*STAR). The company was co-founded by Dr. Gideon Ho, who serves as CEO, and Dr. Dean Tai, the Chief Scientific Officer. Dr. Ho's background includes a PhD in Bioengineering and experience in biophotonics research and commercialization at A*STAR, which directly led to the company's formation. Dr. Tai has extensive experience in R&D, strategic product development, and has been instrumental in establishing global research collaborations and the company's subsidiary in China.

The company operates in the digital pathology market, providing advanced imaging solutions for biological tissues to aid in the diagnosis and research of fibrotic diseases, particularly liver conditions like Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD). HistoIndex serves a clientele of pharmaceutical companies, biotech firms, research institutes, and clinicians involved in preclinical studies and clinical trials. Its business model revolves around providing imaging systems and, more recently, Laboratory Developed Tests (LDTs) as a service. Revenue is generated through these services, which support various stages of the drug development and clinical diagnostic pipeline.

HistoIndex's core technology is a stain-free digital pathology platform that utilizes Second Harmonic Generation (SHG) and Two-Photon Excitation (TPE) microscopy. This biophotonic technology captures high-resolution images of unstained tissue biopsies, which are then analyzed by proprietary AI-based algorithms. This approach avoids the inconsistencies and variabilities associated with traditional tissue staining, providing objective and quantitative analysis of fibrosis and other morphological features. A key product is the Genesis®200, the world's first stain-free multiphoton imaging system, launched in 2013. More recently, the company launched its FibroSIGHT™ and FibroSIGHT™ Plus LDTs in the U.S., which offer automated quantitative fibrosis analysis to assist clinicians in diagnosing and tracking MASH. This provides a continuous scale for measuring fibrosis, offering more detailed insights than traditional categorical scoring methods.

Keywords: digital pathology, fibrosis, MASH, NAFLD, stain-free imaging, Second Harmonic Generation, AI-based analysis, liver disease, clinical trials, biophotonics, tissue analysis, quantitative pathology, medical technology, drug development, precision diagnostics, Lab Developed Test, Genesis®200, FibroSIGHT™, qFibrosis, clinical research